Market research
MSB.AU Mesoblast Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 3.905
- Dividend yield
- Not available
- Beta
- 0.82
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000MSB8
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 3.905
- Dividend yield
- Not available
- Beta
- 0.82
About
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MSB.AU discussion.
5 years, 5 months ago
Mesoblast Limited is currently in a long term downtrend where the price is trading 23.3% below its 200 day moving average.
From a valuation standpoint, the stock is 77.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.8.
Mesoblast Limited's total revenue rose by 1.6% to $2M since the same quarter in the previous year.
Its net income has dropped by 4.5% to $-26M since the same quarter in the previous year.
Finally, its free cash flow fell by 1566.8% to $-32M since the same quarter in the previous year.
Based on the above factors, Mesoblast Limited gets an overall score of 2/5.